Weight-loss doctor says GLP-1 microdosing has no evidence or agreed definition

An obesity physician says there is no legitimate long-term evidence behind "microdosing" GLP-1 drugs and no agreed definition of what a microdose is. The argument appeared in a STAT First Opinion column published May 29, 2026 ^[1].

The author, Jody Dushay, is an assistant professor of medicine at Harvard Medical School and an attending endocrinologist at Beth Israel Deaconess Medical Center ^[1]. She writes that she prescribes only the approved GLP-1 therapies, to people with obesity and weight-related metabolic diseases, and that patients are asking her about microdosing while television and online ads promote it ^[1].

In the column, Dushay walks through the FDA-approved dose levels for Wegovy (semaglutide) and Zepbound (tirzepatide) and states that those are the only doses studied for safety and efficacy ^[1]. She writes that "there are no legitimate long-term data to support" microdosing for weight loss or for any other condition, and that "there isn't even a single definition of microdosing" ^[1].

She frames the trend as one aimed partly at cosmetic weight loss, and writes that friends of hers are "speculating about who's doing it" ^[1]. The column does not supply a definition of microdosing and does not list the specific amounts patients or clinics use under that label ^[1].

The column also does not give figures on how many people microdose, who is prescribing it, what it costs, or whether insurers cover it. None of that has been reported ^[1]. It reports no new trial results; it is an opinion piece describing an evidence gap as the author sees it ^[1].

Why it matters for patients

The practical issue described in the column is not that a lower dose is known to be harmful. It is that a lower dose is largely unstudied. The FDA-approved doses of Wegovy and Zepbound are the only ones with safety and efficacy data behind them, according to the column ^[1].

Because there is no shared definition, the word "microdose" can mean different amounts at different clinics, which makes it hard for patients to compare what they are offered or for researchers to study it ^[1]. It has not been reported what a typical microdose is, how long people stay on one, or what happens when they stop.

Patients taking an FDA-approved dose are in a different position from patients taking something below it, based on the argument in the column: the approved doses are the ones that were tested ^[1]. Whether a compounded or split dose delivers the same amount as an approved dose has not been disclosed in the column ^[1].

The column does not say microdosing is unsafe, and it does not offer dose guidance. It states that the long-term data do not exist either way ^[1].

What happens next

The column was published May 29, 2026 ^[1]. It announces no new study, no FDA action, and no change to drug labels. Whether any trial of lower-than-approved GLP-1 doses is planned has not been reported ^[1].